Search





Search





Markets
/
Stocks
/
nasdaq-tech
/

Bio-Techne Corp

TECH

Add to Watchlist

71.000USD

0.0000.00%

Close 06/26, 16:00（ET）Quotes delayed by 15 min

11.07BMarket Cap

100.60P/E TTM

Bio-Techne Corp

71.000

0.0000.00%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey 图表

Intraday

30m

Today

0.00%

5 Days

+22.54%

1 Month

+47.64%

6 Months

+19.89%

Year to Date

+20.73%

1 Year

+36.96%

Key Figures

--Open

0.000High

0.00Volume

100.60P/E TTM

34.02P/E Dynamic

0.320Dividend TTM

7.86%Turnover Ratio

71.000Prev. Close

0.000Low

0.00Turnover

150.86P/E Static

5.50P/B

0.45%Div Yield TTM

4.22%ROA

72.16052wk High

0.96Volume Ratio

73.36MNet Profit

155.88MShares

0.7057EPS TTM

1.37Beta

5.34%ROE

43.19552wk Low

0.79%Amplitude

67.25%Gross Margin

11.07BMarket Cap

14.20Reward/Risk

2.75%Risk Rate

TradingKey Stock Score of Bio-Techne Corp

Currency: USD Updated: 2026-06-26

Key Insights

Bio-Techne Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 6 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 67.80.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bio-Techne Corp's Score

Industry at a Glance

Industry Ranking

6 / 387

Overall Ranking

43 / 4566

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

20°C



Very Low

Very High

Positive

Bio-Techne Corp Highlights

StrengthsRisks

Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 68.69%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 68.69%.

Overvalued

The company’s latest PE is 100.60, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 178.19M shares, increasing 0.00% quarter-over-quarter.

Held by Lee Ainslie

Star Investor Lee Ainslie holds 5.14M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.56.

Analyst Rating

Based on 18 analysts

Buy

Current Rating

67.801

Target Price

-4.10%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Bio-Techne Corp News

Bio-Techne Acquired by Merck for $11.3 Billion at a Premium, Jumps Over 20% Premarket.

TradingKey - On June 25, Eastern Time, Germany's Merck Group announced that it will acquire US life sciences company Bio-Techne (TECH) for $73 per share in an all-cash transaction, representing an enterprise value of approximately $11.3 billion.

TradingKeyThu, Jun 25